Search results for "Randomized placebo-controlled trial"

showing 2 items of 2 documents

Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus monteluk…

2004

BACKGROUND: Corticosteroids are considered to be particularly effective in reducing nasal congestion and are therefore recommended as first-line treatment in allergic rhinitis patients with moderate to severe and/or persistent symptoms. OBJECTIVE: We compared the clinical efficacy of fluticasone propionate aqueous nasal spray (FPANS) 200 microg given once daily, administered in mono-therapy or combined therapy with a H1 receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the combined therapy of CTZ plus MSK in the treatment of patients affected by allergic rhinitis to Parietaria during natural pollen exposure. In addition, we examined the effect of…

CyclopropanesMaleAllergySettore MED/09 - Medicina Internamedicine.medical_treatmentseasonal allergic rhinitisAcetatesGastroenterologyImmunology and AllergyMedicineChildFluticasonepollen seasonRandomized placebo-controlled trialBlood Proteinsrespiratory systemEosinophil Granule ProteinsMiddle AgedCetirizineAnesthesiamontelukastHistamine H1 AntagonistsQuinolineseosinophil cationic proteinDrug Therapy CombinationFemaleeosinophilsmedicine.symptommedicine.drugAdultmedicine.medical_specialtyAdolescentImmunologyNasal congestionSulfidesPlaceboFluticasone propionateDrug Administration ScheduleRibonucleasesDouble-Blind MethodInternal medicineHumansRandomized placebo-controlled trial; fluticasone; cetirizine; montelukast; seasonal allergic rhinitisGlucocorticoidsMontelukastAdministration IntranasalAnalysis of Variancerhinorrheafluticasone propionatebusiness.industrynasal lavageRhinitis Allergic Seasonalmedicine.diseaseCetirizineAndrostadienesParietariaNasal sprayFluticasoneLeukotriene AntagonistsNasal administrationbusinessClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for…

2004

BACKGROUND: H 1 -receptor antagonists are considered to be particularly effective in reducing pruritus, and they are therefore recommended as first-line treatment in patients with chronic idiopathic urticaria (CIU). Recently, antileukotriene receptors have been used in patients with CIU, either administered as monotherapy or combined with H 1 -receptor antagonists. OBJECTIVE: We compared the clinical efficacy of 5 mg of desloratadine administered once daily either as monotherapy or combined with a leukotriene antagonist, 10 mg of montelukast daily, and 10 mg of montelukast administered daily as monotherapy for the treatment of patients affected by CIU with placebo. METHODS: One hundred sixt…

AdultCyclopropanesMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingSettore MED/09 - Medicina InternaAdolescentUrticariamedicine.medical_treatmentImmunologyPlacebo-controlled studyRandomized placebo-controlled trial; desloratadine; montelukast; chronic idiopathic urticariaAcetatesSulfidesPlaceboGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineImmunology and AllergyHumansMontelukastAgedDesloratadineLeukotriene E4Leukotriene receptorbusiness.industrydesloratadineRandomized placebo-controlled trialLoratadineMiddle AgedAntileukotrieneTreatment OutcomechemistryAnesthesiachronic idiopathic urticariaChronic DiseasemontelukastQuinolinesLeukotriene AntagonistsFemalebusinessmedicine.drug
researchProduct